ScreenerHero
ACBAurora Cannabis Inc.
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · auroramj.com
5.290CAD+0.76%Mkt Cap: 242.06M $P/E: —

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and m…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap242.06M $
Enterprise Value191.66M $
Revenue (TTM)228.73M $
Gross Profit99.52M $
Net Income (TTM)-99.02M $
Revenue/Share3.938 USD
Last Price5.290 CAD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees1.0K
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA05156X8843
Valuation
P/E (Trailing)—
P/E (Forward)-58.33
PEG—
EV/EBITDA-8.79
EV/Revenue0.84
P/S1.06
P/B0.63
EPS (TTM)-0.92
EPS (Forward)-0.09
52W Range
3.59030% of range9.330
52W High9.330 CAD
52W Low3.590 CAD
Profitability
Gross Margin42.62%
Oper. Margin-12.92%
EBITDA Margin-9.54%
Profit Margin-42.41%
ROE-26.56%
ROA-22.62%
Growth
Revenue Growth-8.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.84M $
CapEx (TTM)16.42M $
FCF Margin-6.38%
FCF Yield-6.03%
Net Debt-56.33M $
Net Debt/EBITDA2.58
Balance Sheet
Debt/Equity0.05
Current Ratio5.36
Quick Ratio1.92
Book Value/Sh8.326 CAD
Cash/Share1.542 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 11, 2020
Splits
Last Split1:10
Split DateFeb 20, 2024
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.380 CAD
Upside (mean)+1.7%
Target Range4.000 CAD – 8.000 CAD
CAD4.000+1.7% to meanCAD8.000
# Analysts5
Ownership
Shares Out.63.31M
Float64.46M
Insiders1.21%
Institutions9.34%
Short Interest
Short Ratio8.0d
Short % Out.3.89%
Shares Short2.28M
Short (prev mo.)1.99M
Technical
SMA 504.160 (+27.2%)
SMA 2005.081 (+4.1%)
Beta1.34
S&P 52W Chg18.16%
Avg Vol (30d)493.54K
Avg Vol (10d)796.66K
Technical Indicators
RSI (14)73.4
MACD0.3051
MACD Signal0.1561
MACD Hist.+0.1490
BB Upper5.503 CAD
BB Middle4.258 CAD
BB Lower3.013 CAD
BB Width58.50%
ATR (14)0.2409 CAD
Vol Ratio (20d)0.70x